According to an analysis of initial public offering (IPO) data from 2013, xconomy’s National Biotech Editor Luke Timmerman has concluded that Boston is the clear biotech-cluster winner, with eight completed IPOs raising $769.6 million. Combining data for New York and New Jersey, an equal number of companies completed IPOs this year, but raised less at $668.2 million. Noting that 15 more biotech companies are currently scheduled to go public, based on U.S. Securities and Exchange Commission filings, Timmerman suggests that the ranking could change given that just one more Boston company is "in the queue," while San Diego and Philadelphia have the most in line. So far this year, 45 life sciences companies have raised a combined $3.9 billion through IPOs. See xconomy.com, November 4, 2013.